IMARC Group, a leading market research company, has recently releases report titled “Biosimilar Market Size, Share, Trends and Forecast by Molecule, Indication, Manufacturing Type, and Region, 2025-2033”. The study provides a detailed analysis of the industry, including the global biosimilar market trends, share, size and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
The global biosimilar market size was valued at USD 26.5 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 185.1 Billion by 2033, exhibiting a CAGR of 24.1% from 2025-2033. Europe currently dominates the market. The expiration of patents for major biological drugs, growing awareness about the efficacy and cost-effectiveness of biosimilars, the rising prevalence of chronic diseases worldwide, and continual advancements in biopharmaceutical manufacturing technologies are some of the major factors boosting the biosimilar market share.
Global Biosimilar Market Trends:
The ongoing advancements in biomanufacturing technologies, which enhance production efficiency and reduce costs by enabling more scalable and economically viable production of complex biopharmaceuticals and biologics, are strengthening the market growth. In line with this, increasing government initiatives and incentives to promote biosimilar adoption, including streamlined regulatory pathways and reimbursement policies, are contributing to the expansion of this market. Besides this, increasing investment in research and development (R&D) of innovative biosimilar formulations, including those targeting rare diseases and new therapeutic areas, is supporting the market growth.
Factors Affecting the Growth of the Biosimilar Market Industry:
- Increasing demand for cost-effective biologic treatments:
As biologic drugs have become integral to the treatment of various chronic and complex diseases, the demand for these therapies has surged. However, biological treatments are often associated with high costs, which can be a significant burden on healthcare systems and patients. Biosimilars, which are highly similar to approved biologics but are typically offered at lower prices, provide a cost-effective alternative. This price advantage makes biosimilars an attractive option for healthcare providers looking to manage treatment costs while maintaining the efficacy and safety of biological therapies. The shift towards value-based healthcare models and the need to reduce overall healthcare expenditures are driving the adoption of biosimilars as a more affordable alternative to original biologics, contributing to market growth.
- Patent expirations of major biologic drugs:
The expiration of patents for blockbuster biologic drugs opens the market for biosimilars, as pharmaceutical companies seek to capitalize on the opportunity to introduce similar but less costly versions of these drugs. When a biologic drug's patent expires, other manufacturers can develop biosimilars that replicate the original drug's therapeutic effects. This patent cliff creates a significant opportunity for biosimilar developers to enter the market and offer competitive pricing. For example, the expiration of patents for drugs such as Remicade, Humira, and Enbrel has led to the introduction of multiple biosimilars, increasing market competition and driving growth. The ability to leverage existing clinical data and regulatory pathways established for the reference biologics also facilitates the development and approval of new biosimilars, thus bolstering the market demand.
- Growing prevalence of chronic diseases and complex health conditions:
The rising incidence of chronic diseases such as diabetes, rheumatoid arthritis, and cancer is fueling the demand for biologic treatments, which are often used to manage these conditions. As the prevalence of these diseases continues to grow, there is an increasing need for effective and affordable treatment options. Biosimilars offer a solution by providing more accessible alternatives to expensive biologic therapies. The expansion of biosimilar offerings helps address the treatment gap by making advanced therapies more available to a larger patient population. Additionally, the increasing focus on personalized medicine and targeted therapies further supports the development of biosimilars that can address specific patient needs and enhance treatment outcomes, impelling the market demand.
Request to Get the Sample Report: https://www.imarcgroup.com/biosimilar-market/requestsample
Biosimilar Market Report Segmentation:
Breakup By Molecule:
- Infliximab
- Insulin Glargine
- Epoetin Alfa
- Etanercept
- Filgrastim
- Somatropin
- Rituximab
- Follitropin Alfa
- Adalimumab
- Pegfilgrastim
- Trastuzumab
- Bevacizumab
- Others
Infliximab accounts for the majority of shares due to its widespread use in treating chronic autoimmune diseases such as rheumatoid arthritis and Crohn's disease.
Breakup By Indication:
- Auto-Immune Diseases
- Blood Disorder
- Diabetes
- Oncology
- Growth Deficiency
- Female Infertility
- Others
Autoimmune diseases dominate the market as biologics, and biosimilars are highly effective in managing conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Breakup By Manufacturing Type:
- In-house Manufacturing
- Contract Manufacturing
In-house manufacturing represents the majority of shares because it enables better control over production quality and reduces reliance on third-party manufacturers, ensuring compliance with strict regulatory standards.
Breakup By Region:
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Rest of Europe
- United States
- Japan
- India
- South Korea
- Rest of the World
Europe holds the leading position due to its well-established regulatory pathways for biosimilars and strong government support for biosimilar adoption.
Top Biosimilar Market Leaders:
The biosimilar market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies.
Some of the key players in the market are:
- Sandoz International GmbH
- Pfizer Inc.
- Teva Pharmaceutical Industries Limited
- Celltrion Inc.
- Biocon Limited
- Samsung Biologics
- Amgen, Inc.
- Dr. Reddy's Laboratories Limited
- Stada Arzneimittel Ag.
Speak to An Analyst: https://www.imarcgroup.com/request?type=report&id=497&flag=C
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
Comments
0 comment